Steminent Biotherapeutics Inc. (TPEX:7729)
Taiwan · Delayed Price · Currency is TWD 78.90
+4.00 (5.34%)
At close: Jul 9, 2026
Steminent Biotherapeutics Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
5.26B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 941.00K | 305.00K | 47.96% |
| Dec 31, 2022 | 636.00K | -1.49M | -70.01% |
| Dec 31, 2021 | 2.12M | -49.35M | -95.88% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sinphar Pharmaceutical | 3.39B |
| Medigen Biotechnology | 1.34B |
| Mycenax Biotech | 815.34M |
| Genovate Biotechnology | 471.48M |
| Pharmosa Biopharm | 69.06M |
| OBI Pharma | 49.68M |
| UnicoCell Biomed | 26.54M |
| AnnJi Pharmaceutical | 7.55M |